Janux Therapeutics, Inc. (JANX) stock forecast and price target
Price $11.37 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($11.37)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-1.57 | +14.0% | $27M |
| Next fiscal year ends December 31, 2027 | $-2.55 | −62.1% | $6M |
| Next quarter ends December 31, 2026 | $-0.51 | −0.2% | $4M |
| Quarter after ends March 31, 2027 | $-0.56 | −44.6% | $2M |
Consensus of the analysts covering Janux Therapeutics, updated daily. In the last 30 days 5 estimates were raised and 1 lowered.
Frequently asked questions
What is the Janux Therapeutics stock price target?
The average 12-month target from 14 analysts is $33.14, 191.5% above the current price of $11.37 Targets range from $15.00 to $60.00.
Is Janux Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 13 buy, 2 hold, 1 strong sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Janux Therapeutics expected to earn?
Analysts expect EPS of $-1.57 for the fiscal year ending December 31, 2026 and $-2.55 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.